PURPOSE: Alzheimer's disease (AD) is the most common neurodegenerative disorder characterized by progressive decline in learning, memory, and executive functions. In addition to cognitive and behavioral deficits, vision disturbances have been reported in early stage of AD, well before the diagnosis is clearly established. To further investigate ocular abnormalities, a novel AD transgenic rat model was analyzed. METHODS: Transgenic (Tg) rats (TgF344-AD) heterozygous for human mutant APPswe/PS1ΔE9 and age-matched wild type (WT) rats, as well as 20 human postmortem retinal samples from both AD and healthy donors were used. Visual function in the rodent was analyzed using the optokinetic response and luminance threshold recording from the superior colliculus. Immunohistochemistry on retinal and brain sections was used to detect various markers including amyloid-β (Aβ) plaques. RESULTS: As expected, Aβ plaques were detected in the hippocampus, cortex, and retina of Tg rats. Plaque-like structures were also found in two AD human whole-mount retinas. The choroidal thickness was significantly reduced in both Tg rat and in AD human eyes when compared with age-matched controls. Tg rat eyes also showed hypertrophic retinal pigment epithelial cells, inflammatory cells, and upregulation of complement factor C3. Although visual acuity was lower in Tg than in WT rats, there was no significant difference in the retinal ganglion cell number and retinal vasculature. CONCLUSIONS: In this study, we observed pathological changes in the choroid and in RPE cells in the TgF344-AD rat model; choroidal thinning was observed further in human AD retina. Along with Ab deposition, the inflammatory response was manifested by microglial recruitment and complement activation. Further studies are needed to elucidate the significance and mechanisms of these pathological changes [corrected].
PURPOSE:Alzheimer's disease (AD) is the most common neurodegenerative disorder characterized by progressive decline in learning, memory, and executive functions. In addition to cognitive and behavioral deficits, vision disturbances have been reported in early stage of AD, well before the diagnosis is clearly established. To further investigate ocular abnormalities, a novel AD transgenic rat model was analyzed. METHODS: Transgenic (Tg) rats (TgF344-AD) heterozygous for human mutant APPswe/PS1ΔE9 and age-matched wild type (WT) rats, as well as 20 human postmortem retinal samples from both AD and healthy donors were used. Visual function in the rodent was analyzed using the optokinetic response and luminance threshold recording from the superior colliculus. Immunohistochemistry on retinal and brain sections was used to detect various markers including amyloid-β (Aβ) plaques. RESULTS: As expected, Aβ plaques were detected in the hippocampus, cortex, and retina of Tg rats. Plaque-like structures were also found in two AD human whole-mount retinas. The choroidal thickness was significantly reduced in both Tg rat and in AD human eyes when compared with age-matched controls. Tg rat eyes also showed hypertrophic retinal pigment epithelial cells, inflammatory cells, and upregulation of complement factor C3. Although visual acuity was lower in Tg than in WT rats, there was no significant difference in the retinal ganglion cell number and retinal vasculature. CONCLUSIONS: In this study, we observed pathological changes in the choroid and in RPE cells in the TgF344-AD rat model; choroidal thinning was observed further in humanAD retina. Along with Ab deposition, the inflammatory response was manifested by microglial recruitment and complement activation. Further studies are needed to elucidate the significance and mechanisms of these pathological changes [corrected].
Authors: Dilsher S Dhoot; Siya Huo; Alex Yuan; David Xu; Sunil Srivistava; Justis P Ehlers; Elias Traboulsi; Peter K Kaiser Journal: Br J Ophthalmol Date: 2012-10-23 Impact factor: 4.638
Authors: Robert M Cohen; Kavon Rezai-Zadeh; Tara M Weitz; Altan Rentsendorj; David Gate; Inna Spivak; Yasmin Bholat; Vitaly Vasilevko; Charles G Glabe; Joshua J Breunig; Pasko Rakic; Hayk Davtyan; Michael G Agadjanyan; Vladimir Kepe; Jorge R Barrio; Serguei Bannykh; Christine A Szekely; Robert N Pechnick; Terrence Town Journal: J Neurosci Date: 2013-04-10 Impact factor: 6.167
Authors: Heiko Braak; Irina Alafuzoff; Thomas Arzberger; Hans Kretzschmar; Kelly Del Tredici Journal: Acta Neuropathol Date: 2006-08-12 Impact factor: 17.088
Authors: Dawn A Sim; Pearse A Keane; Hemal Mehta; Simon Fung; Javier Zarranz-Ventura; Marcus Fruttiger; Praveen J Patel; Catherine A Egan; Adnan Tufail Journal: Invest Ophthalmol Vis Sci Date: 2013-04-23 Impact factor: 4.799
Authors: Rameshwar Patil; Yosef Koronyo; Alexander V Ljubimov; Brenda Salumbides; Adam Mamelak; Pallavi R Gangalum; Hui Ding; Jose Portilla-Arias; Eggehard Holler; Pramod Butte; Maya Koronyo-Hamaoui; Julia Y Ljubimova; Keith L Black Journal: Bangk Med J Date: 2015-09
Authors: Yosef Koronyo; David Biggs; Ernesto Barron; David S Boyer; Joel A Pearlman; William J Au; Shawn J Kile; Austin Blanco; Dieu-Trang Fuchs; Adeel Ashfaq; Sally Frautschy; Gregory M Cole; Carol A Miller; David R Hinton; Steven R Verdooner; Keith L Black; Maya Koronyo-Hamaoui Journal: JCI Insight Date: 2017-08-17
Authors: Harald Hampel; Nicola Toschi; Claudio Babiloni; Filippo Baldacci; Keith L Black; Arun L W Bokde; René S Bun; Francesco Cacciola; Enrica Cavedo; Patrizia A Chiesa; Olivier Colliot; Cristina-Maria Coman; Bruno Dubois; Andrea Duggento; Stanley Durrleman; Maria-Teresa Ferretti; Nathalie George; Remy Genthon; Marie-Odile Habert; Karl Herholz; Yosef Koronyo; Maya Koronyo-Hamaoui; Foudil Lamari; Todd Langevin; Stéphane Lehéricy; Jean Lorenceau; Christian Neri; Robert Nisticò; Francis Nyasse-Messene; Craig Ritchie; Simone Rossi; Emiliano Santarnecchi; Olaf Sporns; Steven R Verdooner; Andrea Vergallo; Nicolas Villain; Erfan Younesi; Francesco Garaci; Simone Lista Journal: J Alzheimers Dis Date: 2018 Impact factor: 4.472
Authors: Bliss Elizabeth O'Bryhim; Rajendra S Apte; Nathan Kung; Dean Coble; Gregory P Van Stavern Journal: JAMA Ophthalmol Date: 2018-11-01 Impact factor: 7.389